GM-CSF Promotes Immune Response and Survival in a Mouse Model of COVID-19.

ABSTRACT: COVID-19 results in increased expression of inflammatory cytokines, but inflammation-targeting clinical trials have yielded poor to mixed results. Our studies of other disorders with an inflammatory component, including Alzheimer's disease, chemobrain, Down syndrome, normal aging, and West Nile Virus infection, showed that treatment with the 'pro-inflammatory' cytokine granulocyte-macrophage colony stimulating factor (GM-CSF) in humans or mouse models alleviated clinical, behavioral, and pathological features. We proposed that human recombinant GM-CSF (sargramostim) be repurposed to promote both the innate and adaptive immune responses in COVID-19 to reduce viral load and mortality¹. Here, we report the results of a placebo-controlled study of GM-CSF in human ACE2 transgenic mic

SUBMITTER: Kendall LV 

PROVIDER: S-EPMC8811947 | biostudies-literature | 2022 Jan

REPOSITORIES: biostudies-literature